Multiple Sclerosis and Neuroinflammatory Disease
Clinical research is concentrated on relapsing-remitting multiple sclerosis, with attention to disease activity, lesion burden, and long-term control of inflammatory progression.
- Multiple sclerosis disease activity
- Relapsing-remitting multiple sclerosis
- Magnetic resonance imaging lesion monitoring
Interest extends to outcomes linked with sustained absence of clinical and radiological activity, including NEDA-3 as a key therapeutic endpoint.
Radiologically Isolated Syndrome
Research activity also includes radiologically isolated syndrome, focusing on early identification of individuals at risk of developing symptomatic demyelinating disease.
- Radiologically isolated syndrome
- Early demyelinating disease
- MRI-based risk assessment
Therapeutic interest in this area centers on imaging markers of new inflammatory activity and the transition from incidental findings to clinically manifest disease.
Autologous Haematopoietic Stem Cell Transplantation
The sponsor supports research in aggressive multiple sclerosis involving autologous haematopoietic stem cell transplantation as a treatment strategy for difficult-to-control disease.
- Autologous haematopoietic stem cell transplantation
- Aggressive multiple sclerosis
- Disease remission
Relevant outcomes include sustained suppression of disease activity and achievement of no evidence of disease activity over extended follow-up.
Immunomodulation and Vaccine-Based Approaches
Another area of interest is immunomodulatory therapy, including vaccine-based strategies explored in relation to early multiple sclerosis risk and immune response modulation.
- Immunomodulation
- Vaccine-based therapy
- Immune response modulation
This reflects a focus on interventions that may influence inflammatory pathways and alter the course of central nervous system autoimmunity.
